Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (1821)	9/8/2003 7:41:55 PM
From: Mike	Read Replies (1) \| Respond to of 3044

IJ, Your one of the few on this board that has "seen the light". Now remember this is my conjecture on what MDCO is having on MLNM. But I see deep trouble for MLNM for the next two qtrs. Remember this is a great drug but could be very vulnerable to the data that will be presented for Replace II. I have been very interested in the 2b/3a market and the lack of trials comparing Reopro to Integrilin. The Epistent and the Esprit trial combined don't come close to equaling the total number of patients enrolled in Replace II. MDCO has as much data on Integrilin as MLNM has for comparison. So my point is just to know what is possibly going to happen to MLNM. I have been very forward in saying that I am long 21,000 shares of MDCO. So Irwin take my information for what it is worth and I am not here to state lies or "self promote" MDCO. It doesn't need any help. The market will take care of that but I feel MDCO is a great investment even at the current high. Thanks for your kind supportive words, Mike